0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Fc gamma RIV / CD16-2

Fc gamma RIV / CD16-2

Brief Information

Name:P-selectin glycoprotein ligand-1
Target Synonym:P-selectin glycoprotein ligand 1,PSGL-1,SELPLG,Selectin P Ligand,Cutaneous Lymphocyte-Associated Associated Antigen,CD162 Antigen,CD162,PSGL1,CLA
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
FC4-M82E8 Mouse Biotinylated Mouse Fc gamma RIV / CD16-2 Protein, His,Avitag™ (HPLC & BLI verified)
FC4-M82E8-structure
FC4-M82E8-sds
FC4-M82E8-hplc
FC4-M52H3 Mouse Mouse Fc gamma RIV / CD16-2 Protein, His Tag (MALS verified)
FC4-M52H3-structure
FC4-M52H3-sds
ACRO Quality

Part of Bioactivity data

FC4-M82E8-SPR
 Fc gamma RIV / CD16-2 SPR

Biotinylated Mouse Fc gamma RIV, His,Avitag (BLI verified) (Cat. No. FC4-M82E8) captured on Biotin CAP - Series S sensor Chip can bind Herceptin with an affinity constant of 0.186 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

FC4-M82E8-SPR
 Fc gamma RIV / CD16-2 SPR

Biotinylated Mouse Fc gamma RIV, His,Avitag (BLI verified) (Cat. No. FC4-M82E8) captured on Biotin CAP - Series S sensor Chip can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), Ultra-low endotoxin (Cat. No. CDE-M120a) with an affinity constant of 31.7 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Customer Reviews

Synonym Name

Fc gamma RIV,CD16-2,Fcgr4

Background

FcgR4(Low affinity immunoglobulin gamma Fc region receptor IV) is also known as CD16-2, FcgammaRIV, receptor for the Fc region of immunoglobulin gamma . Also acts as a receptor for the Fc region of immunoglobulin epsilon . Binds with intermediate affinity to both IgG2a and IgG2b . Does not display binding to IgG1 or IgG3. Plays a role in promoting bone resorption by enhancing osteoclast differentiation following binding to IgG2a. Binds with low affinity to both the a and b allotypes of IgE. Has also been shown to bind to IgE allotype a only but not to allotype b. Binding to IgE promotes macrophage-mediated phagocytosis, antigen presentation to T cells, production of proinflammatory cytokines and the late phase of cutaneous allergic reactions

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Cepeprubart SelK-2 Phase 2 Clinical Selexys Venous Thromboembolism; Asthma; Pulmonary Disease, Chronic Obstructive Details
Leiolizumab ALTB-268; AbGn-168H2; AbGn 168H2; AbGn-268 Phase 2 Clinical Colitis, Ulcerative Details
Neihulizumab AbGn-168; AbGn-168H Phase 1 Clinical Abgenomics Graft vs Host Disease; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic Details
SSGJ-617 SSGJ-617; SSGJ617; 61X; VTX-0811; 617 Phase 1 Clinical Verseau Therapeutics Inc Solid tumours Details
Cepeprubart SelK-2 Phase 2 Clinical Selexys Venous Thromboembolism; Asthma; Pulmonary Disease, Chronic Obstructive Details
Leiolizumab ALTB-268; AbGn-168H2; AbGn 168H2; AbGn-268 Phase 2 Clinical Colitis, Ulcerative Details
Neihulizumab AbGn-168; AbGn-168H Phase 1 Clinical Abgenomics Graft vs Host Disease; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic Details
SSGJ-617 SSGJ-617; SSGJ617; 61X; VTX-0811; 617 Phase 1 Clinical Verseau Therapeutics Inc Solid tumours Details

This web search service is supported by Google Inc.

totop

Laisser un message